36
Participants
Start Date
December 12, 2022
Primary Completion Date
December 12, 2023
Study Completion Date
December 12, 2023
MEDI0618
Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
Placebo
Four doses of IV placebo or SC placebo administered once every two weeks.
Research Site, Berlin
Lead Sponsor
AstraZeneca
INDUSTRY